Cipher PharmaceuticalsCipher is a specialty pharmaceutical company with a robust and diversified portfolio of commercial and early to late-stage products ProductsPipeline NewsCipher Pharmaceuticals Announces Renewal of Normal Course Issuer Bid September 8, 2021Cipher Reports 30% Revenue Growth and 40% Adjusted EBITDA Growth in Second Quarter of 2021, Driven by Strength in Epuris and Absorica August 12, 2021Events Q1 2020 Results Conference Call/Webcast Friday, May 8, 2020 Webcast Replay Investors Financial Reports Investor Presentation Corporate Governance Documents Webcasts
